Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Juni 2014 13:06 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus

PHILADELPHIA, June 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon® N, inhibits...
14. Mai 2014 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Biopharma Formally Collaborates With the Swiss Department of Defense, Civil Protection and Sports to Study Alferon(R) Against Tamiflu Resistant Influenza Virus Strains

PHILADELPHIA, May 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it has entered into a formal collaborative research agreement...
05. Mai 2014 08:30 ET | Quelle: AIM ImmunoTech Inc.

Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro

PHILADELPHIA, May 5, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon® N, significantly inhibited the replication...
08. April 2014 08:30 ET | Quelle: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction

PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and...
20. August 2013 11:21 ET | Quelle: Hemispherx Biopharma, Inc.

Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Reduce - Influenza Spread

PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N®, will be featured as part of a new...
09. August 2013 16:23 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2013

PHILADELPHIA, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended June 30, 2013. The net loss (including non-cash effects) was...
29. Juli 2013 08:00 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Appoints Peter W. Rodino III, Esq. to the Board of Directors and to Serve as Chairman of the Company's Audit Committee

PHILADELPHIA, July 29, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that effective July 23, 2013, the Board of Directors of Hemispherx...